We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Lung Surgery No Help for Some Emphysema Patients

By HospiMedica staff writers
Posted on 27 Aug 2001
A study has found that certain advanced emphysema patients not only receive little benefit from lung volume reduction surgery (LVRS) but are at unacceptable risk of death from the procedure. More...
Conducted by researchers from Columbia Presbyterian Medical Center (NY, NY, USA), the study is to appear in the October 11, 2001, issue of The New England Journal of Medicine (NEJM). However, because of the importance of the results, the editors have already posted the study findings on the journal's website.

The study, called NETT (National Emphysema Treatment Trial), is a five-year, multicenter randomized trial designed to evaluate the role of LVRS in the treatment of severe emphysema. Of the 1,033 current participants, 140 met the high-risk criteria and 69 underwent surgery. These patients had a 16% 30-day mortality rate. In contrast, no deaths were reported in the medical treatment group. Furthermore, high-risk patients who survived the surgery were found to have only slightly improved functional outcomes and quality-of-life scores six months later. As a result of these findings, the study is no longer enrolling high-risk patients in the study.

"This is exactly the kind of insight we hope to gain from NETT,” said Dr. Claude Lenfant, director of the U.S. National Heart, Lung, and Blood Institute, the primary sponsor of the study. "We expect the final results of NETT will guide us further in determining if and when this procedure should be used to treat emphysema.”


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.